Literature DB >> 2606823

Penetration into lung tissue after intravenous administration of amoxycillin/clavulanate.

A L Cox1, J M Meewis, R Horton.   

Abstract

In order to investigate the penetration of amoxycillin and clavulanate into lung tissue, ten patients with a malignancy requiring a pulmonary resection, receiving 2000 mg amoxycillin and 200 mg clavulanate by intravenous injection, were studied. Samples of whole blood were taken before dosing and at the time of tissue removal. One to five grams of healthy lung tissue was taken from a segment or lobe other than that in which the tumour was located. All serum and tissue samples were analysed by a microbiological assay. The mean period to elapse before serum sample collection was 41.8 min at which time the mean concentrations were amoxycillin 71.3 and clavulanate 7.8 mg/l. The mean period to elapse before tissue collection was 54.3 min at which time the mean concentrations were amoxycillin 34.1 and clavulanate 2.3 mg/kg. These levels of amoxycillin and clavulanate are high enough to inhibit important pathogens in the lower respiratory tract.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2606823     DOI: 10.1093/jac/24.suppl_b.87

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  7 in total

Review 1.  New formulations of amoxicillin/clavulanic acid: a pharmacokinetic and pharmacodynamic review.

Authors:  Amparo Sánchez Navarro
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 2.  Drug treatment of pneumonia in the hospital. What are the choices?

Authors:  M Aoun; J Klastersky
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

3.  Development of a new experimental model of penicillin-resistant Streptococcus pneumoniae pneumonia and amoxicillin treatment by reproducing human pharmacokinetics.

Authors:  L Piroth; L Martin; A Coulon; C Lequeu; M Duong; M Buisson; H Portier; P Chavanet
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

Review 4.  Amoxicillin/clavulanic acid. An update of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  P A Todd; P Benfield
Journal:  Drugs       Date:  1990-02       Impact factor: 9.546

5.  Development of experimental pneumonia by infection with penicillin-insensitive Streptococcus pneumoniae in guinea pigs and their treatment with amoxicillin, cefotaxime, and meropenem.

Authors:  C Ponte; A Parra; E Nieto; F Soriano
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

6.  Penetration of amoxycillin/clavulanic acid into bronchial mucosa with different dosing regimens.

Authors:  I M Gould; G Harvey; D Golder; T M Reid; S J Watt; J A Friend; J S Legge; J G Douglas
Journal:  Thorax       Date:  1994-10       Impact factor: 9.139

7.  In vitro activities of co-amoxiclav at concentrations achieved in human serum against the resistant subpopulation of heteroresistant Staphylococcus aureus: a controlled study with vancomycin.

Authors:  J Prieto; L Aguilar; M J Giménez; D Toro; M L Gómez-Lus; R Dal-Ré; I P Balcabao
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.